Medicare Enrolled
Dr. Marc Warmuth, MD
Hematology & Oncology · St Augustine, FL
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Warmuth from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Warmuth? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Warmuth
Dr. Marc Warmuth is a hematology & oncology in St Augustine, FL, with 20 years in practice. Based on federal Medicare data, Dr. Warmuth performed 152,587 Medicare services across 5,084 unique beneficiaries.
Between the years covered by Open Payments, Dr. Warmuth received a total of $775 from 27 pharmaceutical and/or device companies across 48 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Warmuth is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice▲ Top 4% volume in FL$ $775 industry payments
Medicare Practice Summary
Medicare Utilization ↗152,587
Medicare services
Top 4% in FL for hematology & oncology
5,084
Unique beneficiaries
$10
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~7,629 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Contrast dye for imaging (iodine-based) | 51,950 | $0 | $1 |
| Iron infusion (Injectafer) | 37,500 | $1 | $4 |
| Pembrolizumab injection (Keytruda) | 17,400 | $43 | $110 |
| Oxaliplatin chemotherapy injection | 10,960 | $0 | $5 |
| Anti-nausea injection (fosaprepitant) | 9,150 | $0 | $5 |
| Denosumab injection (Prolia/Xgeva) | 3,480 | $18 | $42 |
| Dexamethasone injection (steroid) | 3,420 | $0 | $1 |
| MRI contrast dye injection (gadoterate) | 2,275 | $0 | $25 |
| Epoetin alfa injection (Retacrit) for anemia | 1,990 | $6 | $27 |
| Blood draw (venipuncture) | 1,984 | $8 | $18 |
| Complete blood count (CBC) with differential | 1,949 | $8 | $41 |
| Anti-nausea injection (Aloxi/palonosetron) | 1,550 | $1 | $75 |
| Injection, leucovorin calcium, per 50 mg | 830 | $3 | $20 |
| Injection, granisetron hydrochloride, 100 mcg | 810 | $0 | $41 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 752 | $21 | $90 |
| Office visit, established patient (20-29 min) | 583 | $64 | $104 |
| Injection, fluorouracil, 500 mg | 577 | $2 | $12 |
| Office visit, established patient (30-39 min) | 536 | $92 | $162 |
| Administration of chemotherapy into vein, 1 hour or less | 487 | $95 | $355 |
| Ct scan of chest with contrast | 440 | $52 | $500 |
| Blood creatinine level | 344 | $5 | $29 |
| CT scan of abdomen and pelvis with contrast | 327 | $166 | $535 |
| Administration of chemotherapy into vein, each additional hour | 227 | $21 | $80 |
| Drug injection, under skin or into muscle | 220 | $10 | $42 |
| Injection, carboplatin, 50 mg | 218 | $2 | $57 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 202 | $401 | $1,000 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 197 | $1,093 | $2,400 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 169 | $55 | $115 |
| Injection, diphenhydramine hcl, up to 50 mg | 146 | $1 | $4 |
| Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services | 139 | $73 | $70 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 128 | $47 | $160 |
| Administration of additional new drug or substance into vein, 1 hour or less | 126 | $48 | $175 |
| Mri scan of brain before and after contrast | 112 | $123 | $560 |
| Hospital follow-up visit, moderate complexity | 89 | $63 | $115 |
| Injection, zoledronic acid, 1 mg | 88 | $6 | $282 |
| Initial hospital admission, moderate complexity | 80 | $102 | $225 |
| CT scan of chest, without contrast | 77 | $48 | $310 |
| Injection of additional new drug or substance into vein | 71 | $12 | $55 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 68 | $24 | $84 |
| Administration of additional new drug or substance into vein using push technique | 63 | $41 | $145 |
| Ct scan of soft tissue of neck with contrast | 59 | $73 | $495 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 52 | $15 | $45 |
| Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | 52 | $130 | $950 |
| Mri scan of abdomen before and after contrast | 50 | $141 | $676 |
| Infusion into a vein for hydration, 31-60 minutes | 49 | $25 | $130 |
| New patient office visit (30-44 min) | 49 | $82 | $181 |
| Urinalysis, manual | 46 | $3 | $15 |
| Hospital follow-up visit, low complexity | 46 | $40 | $68 |
| Irrigation of implanted venous access drug delivery device | 40 | $17 | $110 |
| Office visit, established patient, complex (40-54 min) | 40 | $138 | $235 |
| Infusion into a vein for hydration, each additional hour | 37 | $10 | $40 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 36 | $1 | $7 |
| Infusion, normal saline solution , 1000 cc | 36 | $2 | $97 |
| Mri scan of pelvis before and after contrast | 33 | $133 | $670 |
| Ct scan of abdomen and pelvis without contrast | 33 | $77 | $270 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 33 | $15 | $55 |
| Mri scan of lower spinal canal before and after contrast | 32 | $114 | $562 |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 29 | $1 | $21 |
| New patient office visit (45-59 min) | 26 | $125 | $265 |
| Office visit, established patient (10-19 min) | 23 | $43 | $74 |
| Drawing of blood for a medical problem | 22 | $67 | $165 |
| Hospital follow-up visit, high complexity | 19 | $94 | $160 |
| Nuclear medicine study whole body with ct scan | 16 | $1,087 | $2,490 |
| Initial hospital admission, high complexity | 15 | $132 | $330 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
25.3% high complexity
70.5% medium
4.2% routine
Industry Payment Transparency
Open Payments through 2024 ↗$775
Total received (2018-2024)
Avg $111/year across 7 years
Bottom 26% in FL for hematology & oncology
27
Companies
48
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$685 (88.4%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$90 (11.6%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024$221
2023$191
2022$76
2021$69
2020$44
2019$73
2018$101
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Novartis Pharmaceuticals Corporation
$109
Alexion Pharmaceuticals, Inc.
$79
Merck Sharp & Dohme Corporation
$56
Alnylam Pharmaceuticals Inc.
$40
AstraZeneca Pharmaceuticals LP
$40
Genentech USA, Inc.
$40
PFIZER INC.
$38
Daiichi Sankyo Inc.
$35
Incyte Corporation
$34
Janssen Biotech, Inc.
$34
Coherus Biosciences Inc.
$30
Ipsen Biopharmaceuticals, Inc
$27
Taiho Oncology, Inc.
$27
Secura Bio, Inc.
$18
GENZYME CORPORATION
$17
Takeda Pharmaceuticals U.S.A., Inc.
$15
Agios Pharmaceuticals, Inc.
$15
Merck Sharp & Dohme LLC
$14
Eisai Inc.
$14
TESARO, Inc.
$12
Karyopharm Therapeutics Inc.
$12
Gilead Sciences, Inc.
$12
Bayer HealthCare Pharmaceuticals Inc.
$12
Lilly USA, LLC
$12
Astellas Pharma US Inc
$12
JAZZ PHARMACEUTICALS INC.
$11
Aurobindo Pharma USA, Inc.
$11
Top 3 companies account for 31.5% of total payments
Associated products mentioned in payments ›
ALIMTA · EMEND · ENHERTU · ENJAYMO · FRUZAQLA · Farydak · GIVLAARI · IMBRUVICA · INJECTAFER · INQOVI · JAKAFI · KEYTRUDA · KISQALI · LYNPARZA · Lenvima · Lonsurf · MONJUVI · Onivyde · PROMACTA · Polivy · RYBREVANT · SCEMBLIX · Somatuline Depot · TASIGNA · ULTOMIRIS · Udenyca · Ultomiris · VYXEOS · Vitrakvi · XPOVIO · XTANDI · ZEJULA · Zevalin
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (88%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Equivalent to $1 per 100 Medicare services performed
Geographic Context
Hematology & Oncologys within 10 mi
9
Per 100K population
3.1
County median income
$106,169
Nearest hospital
FLAGLER HOSPITAL
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Warmuth is a mixed practice specialist, with above-average Medicare volume (top 4% in FL), and low-engagement industry engagement, with 20 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Warmuth experienced with contrast dye for imaging (iodine-based)?
Based on Medicare claims data, Dr. Warmuth performed 51,950 contrast dye for imaging (iodine-based) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Warmuth receive payments from pharmaceutical companies?
Yes. Dr. Warmuth received a total of $775 from 27 companies across 48 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Warmuth's costs compare to other hematology & oncologys in St Augustine?
Dr. Warmuth's average Medicare payment per service is $10. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Warmuth) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncologys in St Augustine
Browse hematology & oncologys in St Augustine ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncologys in FL
Hematology & Oncologys ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncologys in FL
Which FL hematology & oncologys receive the most from drug and device companies.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
Alexion Pharmaceuticals, Inc. Payments to Doctors
See all physicians who received payments from Alexion Pharmaceuticals, Inc..
By company
Merck Sharp & Dohme Corporation Payments to Doctors
See all physicians who received payments from Merck Sharp & Dohme Corporation.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology